Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy

Kang, Yongbo; Cai, Yue

doi:10.1016/j.jhin.2017.04.007

Cited by 45 publications

(55 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the composition of intestinal microbiota in HBV‐carrier patients shows an increase in the growth rate of E. coli . The intestinal microbiota profile of end‐stage liver disease in CHB patients showed an obvious increase in Enterobacteriaceae , Enterococcus faecalis and Faecalibacterium prausnitzii . Intestinal bacteria with high frequency in CHB patients are illustrated in Table .…”

Section: Intestinal Microbiota In Hbv‐carrier Liver Diseasementioning

confidence: 91%

“…Intestinal bacteria with high frequency in CHB patients are illustrated in Table . Reciprocally, the lower number of intestinal lactic acid species such as Lactobacillus , Pediococcus , Weissella and Leuconostoc has been reported in CHB patients . Furthermore, the amount of Clostridium spp cluster XI and XIVa as well as Bacteroides , Prevotella, and Lactobacillus spp .…”

Section: Intestinal Microbiota In Hbv‐carrier Liver Diseasementioning

confidence: 92%

“…[15][16][17] The intestinal microbiota profile of end-stage liver disease in CHB patients showed an obvious increase in Enterobacteriaceae, Enterococcus faecalis and Faecalibacterium prausnitzii. 1,6 Intestinal bacteria with high frequency in CHB patients are illustrated in Table 1. Reciprocally, the lower number of intestinal lactic acid species such as Lactobacillus, Pediococcus, Weissella and Leuconostoc has been reported in CHB patients.…”

Section: Hbv-carrier Liver Diseasementioning

confidence: 99%

See 2 more Smart Citations

On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B

Ashraf

2018

Cancer Medicine

View full text Add to dashboard Cite

The chronic infection of hepatitis B virus (HBV) is the most potent risk factor for the development of cirrhosis and hepatocellular carcinoma (HCC). The association of intestinal microbiota alteration with progressive liver disease has been investigated in recent studies. Overgrowth of potentially pathogenic bacteria of gram‐negative species and, in particular, a significant increase in the fecal count of Escherichia coli (E. coli) are characterized in the presence of HCC. This study was conducted to describe the characteristics of the intestinal microbiota related to the presence of HCC in HBV‐carrier patients. The available literature indicates the colonization of E. coli as principal source of portal vein lipopolysaccharide (LPS), in the gut may contribute to the carcinogenesis process by inducing chronic inflammation. This understanding could help to predict the clinical outcomes in HBV‐carrier patients and innovative strategies to reduce the virulence of liver disease from intestinal dysbiosis.

show abstract

Section: Intestinal Microbiota In Hbv‐carrier Liver Diseasementioning

confidence: 91%

Section: Intestinal Microbiota In Hbv‐carrier Liver Diseasementioning

confidence: 92%

Section: Hbv-carrier Liver Diseasementioning

confidence: 99%

See 1 more Smart Citation

On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B

Ashraf

2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Healthy donor FMT, in addition to standard antivirals, was shown to be significantly more effective in clearance of the hepatitis B e antigen when compared to antiviral therapy alone. 71,72 In patients with hepatitis C virus (HCV)-related cirrhosis, the microbial diversity was found to be lower when compared to healthy controls. HCV can alter the GM through The intestinal microbiota influences drug and xenobiotic metabolisms, that can affect drug efficacy and toxicity.…”

Section: Gm In Liver Cancermentioning

confidence: 99%

Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease

Philips¹,

Augustine²,

Yerol³

et al. 2019

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Gut microbiota has been demonstrated to have a significant impact on the initiation, progression and development of complications associated with multiple liver diseases. Notably, nonalcoholic fatty liver diseases, including nonalcoholic steatohepatitis and cirrhosis, severe alcoholic hepatitis, primary sclerosing cholangitis and hepatic encephalopathy, have strong links to dysbiosisor a pathobiological change in the microbiota. In this review, we provide clear and concise discussions on the human gut microbiota, methods of identifying gut microbiota and its functionality, liver diseases that are affected by the gut microbiota, including novel associations under research, and provide current evidence on the modulation of gut microbiota and its effects on specific liver disease conditions.

show abstract

“…In this context, possible mechanisms of action of FMT in such situations include manipulation of the composition of gut microbiota, fortification of the intestinal barrier and suppression of pathogens, and immunomodulation ( Figure 2). 55 A large body of research has demonstrated that alteration of the relative level of the two dominant bacterial divisions (Bacteroidetes and Firmicutes) was related to obesity, [29][30][31][32] namely, the abundance of Bacteroidetes was lower, while the abundance of Firmicutes was higher in obese individuals. Meanwhile, the obese microbiome was shown to be more efficient at absorbing energy from food by digestion compared to the lean microbiome.…”

Section: Fecal Microbiota Transplantation Therapy In Obesitymentioning

confidence: 99%

Gut microbiota and obesity: implications for fecal microbiota transplantation therapy

Kang

Cai

2017

View full text Add to dashboard Cite

Obesity is a major public health issue as it is causally associated with several chronic disorders, including type-2 diabetes, cerebrovascular disease (CVD), and cancer. In the United States and other countries worldwide, the obesity epidemic has drastically impacted the status of health of millions as well as healthcare costs. Aside from poor diet, hygiene, and genetics, there are many other factors thought to play an important role in the emergence of obesity. Nowadays, accumulating evidence is elucidating the relation of dysbiosis of intestinal bacteria with obesity and metabolic disorders. Certain gut microbial strains have been shown to inhibit or attenuate immune responses related to chronic inflammation in experimental models, suggesting that specific species among gut microbiota may play either a protective or a pathogenic role in the progression of obesity. Fecal microbiota transplantation (FMT) can therefore represent a therapeutic approach for obesity treatment. FMT is a relatively straightforward therapy that manipulates the human gastrointestinal (GI) microbiota by transferring healthy donor microbiota into an existing but disturbed microbial ecosystem. However, the relevant scientific work is still in its early stages. In this review, we summarize the cutting-edge research being done into FMT treatment of obesity, current issues in FMT treatment, and the future of FMT and microbial therapeutics.

show abstract

Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy

Cited by 45 publications

References 62 publications

On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B

On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B

Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease

Gut microbiota and obesity: implications for fecal microbiota transplantation therapy

Contact Info

Product

Resources

About